Table 1.
Distribution of clinical characteristics by recreational physical activity category among the 1254 participants with any information on methylation (gene-specific and/or global) and lifetime physical activity in a population-based cohort of women diagnosed with first primary breast cancer, Long Island Breast Cancer Study Project
| Recreational physical activity | Inactive (n = 294) |
<6.36 h/week (n = 497) |
≥6.36 h/week (n = 463) |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Age at diagnosis | |||
| <50 years | 55 (18.71) | 170 (34.21) | 136 (29.37) |
| ≥50 years | 239 (81.29) | 327 (65.79) | 327 (70.63) |
| Menopausal status | |||
| Premenopausal | 55 (19.37) | 187 (38.09) | 148 (32.74) |
| Postmenopausal | 229 (80.63) | 304 (61.91) | 304 (67.26) |
| Family history of breast cancer | |||
| No | 225 (78.13) | 396 (82.16) | 361 (80.94) |
| Yes | 63 (21.88) | 86 (17.84) | 85 (19.06) |
| Body mass index (BMI) | |||
| BMI <25 kg/m2 | 113 (38.97) | 240 (48.58) | 200 (43.67) |
| BMI 25–29.9 kg/m2 | 92 (31.72) | 157 (31.78) | 157 (34.28) |
| BMI ≥30 kg/m2 | 85 (29.31) | 97 (19.64) | 191 (22.05) |
| Cigarette smoking | |||
| Never | 138 (46.94) | 231 (46.48) | 199 (42.98) |
| Current/former | 156 (53.06) | 266 (53.32) | 264 (57.02) |
| History of benign breast disease | |||
| No | 248 (84.35) | 393 (79.07) | 370 (80.09) |
| Yes | 46 (15.65) | 104 (20.93) | 92 (19.91) |
| Cancer type | |||
| In situ | 39 (13.27) | 97 (19.52) | 57 (12.31) |
| Invasive | 255 (86.73) | 400 (80.48) | 406 (87.69) |
| Hormone receptor statusa | |||
| Positive | 158 (81.44) | 252 (78.02) | 260 (79.75) |
| Negative | 36 (18.35) | 71 (21.98) | 66 (20.25) |
| Estrogen receptor status | |||
| Positive | 147 (75.77) | 235 (72.76) | 248 (76.07) |
| Negative | 47 (24.23) | 88 (27.24) | 78 (23.93) |
| Progesterone receptor status | |||
| Positive | 125 (64.43) | 203 (62.85) | 220 (67.48) |
| Negative | 69 (35.57) | 120 (37.15) | 106 (32.52) |
| Tumor size | |||
| <2 cm | 94 (60.26) | 171 (66.28) | 187 (68.75) |
| ≥2 cm | 62 (39.74) | 87 (33.72) | 85 (31.25) |
| Nodal involvement | |||
| 0 | 45 (27.78) | 73 (27.76) | 48 (18.05) |
| 1 | 117 (72.22) | 190 (72.24) | 218 (81.95) |
| Treatment type | |||
| No chemotherapy | 120 (65.57) | 206 (56.59) | 183 (60.00) |
| Chemotherapy | 63 (34.43) | 158 (43.41) | 122 (40.00) |
| No radiation | 75 (40.98) | 148 (40.55) | 113 (36.81) |
| Radiation | 108 (59.02) | 217 (59.45) | 194 (63.19) |
| No hormone therapy | 58 (32.22) | 144 (40.11) | 119 (39.40) |
| Hormone therapy | 122 (67.78) | 215 (59.89) | 183 (60.60) |
a Any estrogen receptor-positive or progesterone receptor-positive tumor